Low-dose chest CT: the lung cancer screening that actually saves lives

Lung cancer kills more people worldwide than any other cancer. It's also one of the few cancers where we have a screening tool that has been proven, in large randomized trials, to reduce mortality. That tool is low-dose computed tomography — LDCT. And yet most people who qualify for it have never been offered the test.

The evidence: two landmark trials

The case for LDCT screening rests on two major studies that together enrolled over 80,000 participants.

The National Lung Screening Trial (NLST), published in 2011, compared annual LDCT to chest X-ray in over 53,000 current and former heavy smokers aged 55–74. The result: a 20% reduction in lung cancer mortality in the LDCT group. This was one of the clearest screening benefits ever demonstrated in oncology.

The NELSON trial, published in 2020, confirmed these findings in a European population of over 15,000 participants. Among men, lung cancer mortality was reduced by 24% at 10 years. Among women, the reduction was even larger — 33%.

Who should get screened

LDCT screening is not for everyone. The evidence supports screening in a specific high-risk population:

• Age 50–80
• 20+ pack-year smoking history (pack-years = packs per day × years smoked)
• Current smoker or quit within the last 15 years

Outside this population, the harms of screening — false positives, unnecessary biopsies, radiation exposure, anxiety — outweigh the benefits. This is exactly the kind of risk stratification that evidence-based preventive medicine requires.

What "low-dose" actually means

A standard diagnostic chest CT delivers roughly 7 millisieverts (mSv) of radiation. A low-dose CT delivers about 1.5 mSv — roughly the same as six months of natural background radiation. The "low-dose" part matters because it makes annual screening feasible without accumulating meaningful radiation risk over time.

The scan takes about 15 seconds. No injection, no preparation, no sedation. You lie down, hold your breath briefly, and it's done.

The false-positive problem

LDCT screening has a significant false-positive rate, and this deserves honest discussion. In the NLST, about 24% of LDCT scans found something abnormal. Of those, 96% turned out to be benign — mostly small lung nodules that needed follow-up imaging but ultimately meant nothing.

This means roughly 1 in 4 people screened will have a finding that causes anxiety and requires additional imaging. A small number will undergo biopsies for lesions that turn out to be harmless. This is a real harm, and any program offering LDCT screening has a responsibility to discuss it openly with patients before the scan.

Why this matters for US patients specifically

LDCT lung screening has been recommended by the USPSTF since 2013 and is covered by Medicare and most private insurance. Despite this, uptake in the US remains shockingly low — estimates suggest only 5–15% of eligible Americans have been screened. The reasons are systemic: many physicians don't bring it up, many patients don't know they qualify, and the process of scheduling and following up is fragmented.

In the Health Detectors program, eligibility assessment happens automatically during the DETECT intake. If your smoking history puts you in the qualifying range, your Quarterback Physician discusses LDCT with you as part of the risk report. It's not something you have to know to ask for — it's part of the system.